Long-term safety of methotrexate in the treatment of rheumatoid arthritis

CER4165
2010 Vol.28, N°5 ,Suppl.61
PI 0065, PF 0067
Review

Free to view
(click on article PDF icon to read the article)

PMID: 21044436 [PubMed]

Received: 15/09/2010
Accepted : 15/09/2010
In Press: 28/10/2010
Published: 28/10/2010

Abstract

Methotrexate (MTX) has been the anchor treatment in rheumatoid arthritis (RA) over the last 15 years, and is used in combination with biologic agents to enhance efficacy over the last decade or so. The safety profile of MTX has been studied over 25 years with very few clinically important adverse events in the weekly low-doses used for RA treatment. The importance of MTX in earlier and more aggressive management of RA patients cannot be overstated. MTX courses show some of the longest continuation rates reported in clinical medicine, due to both effectiveness and safety. The safety profile of MTX indicates that it is among the safest of any mediation used for the treatment of any arthritis. Better information on the effectiveness and safety of weekly-low dose MTX should be communicated to all health professionals involved in the management of RA patients.